Meeting of the National Vaccine Advisory Committee, 96021 [2016-31530]

Download as PDF Federal Register / Vol. 81, No. 250 / Thursday, December 29, 2016 / Notices Dated: December 21, 2016. Joanna Bare, Executive Officer, Division of Management Services, Center for Scientific Review, NIH. [FR Doc. 2016–31543 Filed 12–28–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the National Vaccine Advisory Committee National Vaccine Program Office, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that a meeting is scheduled to be held for the National Vaccine Advisory Committee (NVAC). The meeting will be open to the public; public comment sessions will be held during the meeting. SUMMARY: The meeting will be held on February 7 and 8, 2017. The meeting times and agenda will be posted on the NVAC Web site at http://www.hhs.gov/ nvpo/nvac/meetings/index.html as soon as they become available. ADDRESSES: Pre-registration is required for members of the public who wish to attend the meeting and who wish to participate in the public comment session. Individuals who wish to attend the meeting and/or participate in the public comment session should register at http://www.hhs.gov/nvpo/nvac/ meetings/index.html. Participants may also register by emailing nvpo@hhs.gov or by calling (202) 690–5566 and providing their name, organization, and email address. U.S. Department of Health and Human Services, Hubert H. Humphrey Building, Great Hall, 200 Independence Avenue SW., Washington, DC 20201. The meeting can also be accessed through a live webcast on both days of the meeting. For more information, visit http://www.hhs.gov/nvpo/nvac/ meetings/index.html. FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, U.S. Department of Health and Human Services, Room 715H, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201. Phone: (202) 690–5566; email: nvpo@ hhs.gov. asabaliauskas on DSK3SPTVN1PROD with NOTICES DATES: VerDate Sep<11>2014 18:41 Dec 28, 2016 Jkt 241001 Pursuant to Section 2101 of the Public Health Service Act (42 U.S.C. 300aa–1), the Secretary of Health and Human Services was mandated to establish the National Vaccine Program to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The NVAC was established to provide advice and make recommendations to the Director of the National Vaccine Program on matters related to the Program’s responsibilities. The Assistant Secretary for Health serves as Director of the National Vaccine Program. During the February 2017 NVAC meeting, there will be a discussion of the 21st Century Cures Act and vaccines; an update on the recent mumps outbreaks in the US; presentations on Zika virus disease and the status of Zika vaccine development; presentations on vaccine adverse events and insights from personalized medicine; and the NVAC’s Mid-course Review Working Group will present its findings and draft recommendations for deliberation and vote by the Committee. Please note that agenda items are subject to change as priorities dictate. Information on the final meeting agenda will be posted prior to the meeting on the NVAC Web site: http:// www.hhs.gov/nvpo/nvac/index.html. Public attendance at the meeting is limited to the available space. Individuals who plan to attend in person and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the National Vaccine Program Office at the address/phone listed above at least one week prior to the meeting. For those unable to attend in person, a live webcast will be available. More information on registration and accessing the webcast can be found at http://www.hhs.gov/ nvpo/nvac/meetings/index.html. Members of the public will have the opportunity to provide comments at the NVAC meeting during the public comment periods designated on the agenda. Public comments made during the meeting will be limited to three minutes per person to ensure time is allotted for all those wishing to speak. Individuals are also welcome to submit their written comments. Written comments should not exceed three pages in length. Individuals submitting written comments should email their comments to the National Vaccine Program Office (nvpo@hhs.gov) at least five business days prior to the meeting. SUPPLEMENTARY INFORMATION: PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 96021 Dated: December 21, 2016. Bruce Gellin, Designated Federal Officer, National Vaccine Advisory Committee, Deputy Assistant Secretary for Health. [FR Doc. 2016–31530 Filed 12–28–16; 8:45 am] BILLING CODE 4150–44–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of a meeting of the NIH Clinical Center Research Hospital Board. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The portions of the meeting devoted to the Anonymous Safety Hotline and the laboratories or units and staff involved in the individual reports to the Hotline, staff, as well as discussions regarding non-executive employees holding specific positions in the Clinical Center will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B) and 552b(c)(6), Title 5 U.S.C., as amended. Premature disclosure of the laboratories or units and staff involved in the individual reports could significantly limit the Hotline’s purpose by compromising anonymity. Discussion of specific nonexecutive employees would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: NIH Clinical Center Research Hospital Board. Date: January 13, 2017. Open: 8:30 a.m. to 12:30 p.m. Agenda: Board Chair’s Overview, Remarks from the NIH Director and the New CEO, Clinical Center Focus Groups, Improving the Clinical Center’s Census, Clinical Center Patient and Worker Safety Metrics. Open: 1:30 p.m. to 3:30 p.m. Agenda: IT Infrastructure and Security, Audits of Delayed Reporting—Self-Audit Results and Formal Audit Planning, Facilities Update. Closed: 3:45 p.m. to Adjournment. Agenda: Anonymous Safety Hotline, Clinical Center Employees. E:\FR\FM\29DEN1.SGM 29DEN1

Agencies

[Federal Register Volume 81, Number 250 (Thursday, December 29, 2016)]
[Notices]
[Page 96021]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-31530]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the National Vaccine Advisory Committee

AGENCY: National Vaccine Program Office, Office of the Assistant 
Secretary for Health, Office of the Secretary, Department of Health and 
Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: As stipulated by the Federal Advisory Committee Act, the 
Department of Health and Human Services (HHS) is hereby giving notice 
that a meeting is scheduled to be held for the National Vaccine 
Advisory Committee (NVAC). The meeting will be open to the public; 
public comment sessions will be held during the meeting.

DATES: The meeting will be held on February 7 and 8, 2017. The meeting 
times and agenda will be posted on the NVAC Web site at http://www.hhs.gov/nvpo/nvac/meetings/index.html as soon as they become 
available.

ADDRESSES: Pre-registration is required for members of the public who 
wish to attend the meeting and who wish to participate in the public 
comment session. Individuals who wish to attend the meeting and/or 
participate in the public comment session should register at http://www.hhs.gov/nvpo/nvac/meetings/index.html. Participants may also 
register by emailing nvpo@hhs.gov or by calling (202) 690-5566 and 
providing their name, organization, and email address.

U.S. Department of Health and Human Services, Hubert H. Humphrey 
Building, Great Hall, 200 Independence Avenue SW., Washington, DC 
20201.

    The meeting can also be accessed through a live webcast on both 
days of the meeting. For more information, visit http://www.hhs.gov/nvpo/nvac/meetings/index.html.

FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, U.S. 
Department of Health and Human Services, Room 715H, Hubert H. Humphrey 
Building, 200 Independence Avenue SW., Washington, DC 20201. Phone: 
(202) 690-5566; email: nvpo@hhs.gov.

SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public 
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and 
Human Services was mandated to establish the National Vaccine Program 
to achieve optimal prevention of human infectious diseases through 
immunization and to achieve optimal prevention against adverse 
reactions to vaccines. The NVAC was established to provide advice and 
make recommendations to the Director of the National Vaccine Program on 
matters related to the Program's responsibilities. The Assistant 
Secretary for Health serves as Director of the National Vaccine 
Program.
    During the February 2017 NVAC meeting, there will be a discussion 
of the 21st Century Cures Act and vaccines; an update on the recent 
mumps outbreaks in the US; presentations on Zika virus disease and the 
status of Zika vaccine development; presentations on vaccine adverse 
events and insights from personalized medicine; and the NVAC's Mid-
course Review Working Group will present its findings and draft 
recommendations for deliberation and vote by the Committee. Please note 
that agenda items are subject to change as priorities dictate. 
Information on the final meeting agenda will be posted prior to the 
meeting on the NVAC Web site: http://www.hhs.gov/nvpo/nvac/index.html.
    Public attendance at the meeting is limited to the available space. 
Individuals who plan to attend in person and need special assistance, 
such as sign language interpretation or other reasonable 
accommodations, should notify the National Vaccine Program Office at 
the address/phone listed above at least one week prior to the meeting. 
For those unable to attend in person, a live webcast will be available. 
More information on registration and accessing the webcast can be found 
at http://www.hhs.gov/nvpo/nvac/meetings/index.html.
    Members of the public will have the opportunity to provide comments 
at the NVAC meeting during the public comment periods designated on the 
agenda. Public comments made during the meeting will be limited to 
three minutes per person to ensure time is allotted for all those 
wishing to speak. Individuals are also welcome to submit their written 
comments. Written comments should not exceed three pages in length. 
Individuals submitting written comments should email their comments to 
the National Vaccine Program Office (nvpo@hhs.gov) at least five 
business days prior to the meeting.

    Dated: December 21, 2016.
Bruce Gellin,
Designated Federal Officer, National Vaccine Advisory Committee, Deputy 
Assistant Secretary for Health.
[FR Doc. 2016-31530 Filed 12-28-16; 8:45 am]
BILLING CODE 4150-44-P